The funds will support clinical development of FB102, Forte’s proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases.
These two ETFs have similar investment styles, but there are some key differences.
Nobody can say definitively how the index will move, but history is on investors' side.
The U.S. stock market made patient investors much richer over the last 15 years.
Some of world's top tech companies have driven this ETF higher over the past year.
This ETF may take off along with the index.
This ETF contains some of the world's most important companies in the AI ecosystem.
This growth-focused fund provides heavy exposure to the "Magnificent Seven," but also spreads money across a thousand other stocks.
This growth-focused index fund provides exposure to some of the most innovative companies in the world, including Microsoft, Amazon, Nvidia, and Tesla.
Strong gains across the S&P 500, Dow Jones, and Nasdaq over the last decade are evidence that patience is the key to making money in the stock market.